IL292403A - Crizanelizumab containing an antibody formulation - Google Patents

Crizanelizumab containing an antibody formulation

Info

Publication number
IL292403A
IL292403A IL292403A IL29240322A IL292403A IL 292403 A IL292403 A IL 292403A IL 292403 A IL292403 A IL 292403A IL 29240322 A IL29240322 A IL 29240322A IL 292403 A IL292403 A IL 292403A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
crizanlizumab
concentration
antibody
months
Prior art date
Application number
IL292403A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL292403A publication Critical patent/IL292403A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL292403A 2019-10-30 2020-10-29 Crizanelizumab containing an antibody formulation IL292403A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927720P 2019-10-30 2019-10-30
US201962927716P 2019-10-30 2019-10-30
US201962933692P 2019-11-11 2019-11-11
US201962936269P 2019-11-15 2019-11-15
PCT/US2020/057868 WO2021087050A1 (en) 2019-10-30 2020-10-29 Crizanlizumab containing antibody formulation

Publications (1)

Publication Number Publication Date
IL292403A true IL292403A (en) 2022-06-01

Family

ID=73544317

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292403A IL292403A (en) 2019-10-30 2020-10-29 Crizanelizumab containing an antibody formulation

Country Status (19)

Country Link
US (1) US20220378912A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051236A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023501155A (cg-RX-API-DMAC7.html)
KR (1) KR20220092917A (cg-RX-API-DMAC7.html)
CN (1) CN114828826A (cg-RX-API-DMAC7.html)
AU (1) AU2020373017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022008097A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158921A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001085A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005207A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22033601A (cg-RX-API-DMAC7.html)
IL (1) IL292403A (cg-RX-API-DMAC7.html)
JO (1) JOP20220097A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022005044A (cg-RX-API-DMAC7.html)
MY (1) MY209141A (cg-RX-API-DMAC7.html)
PE (1) PE20221276A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551041A1 (cg-RX-API-DMAC7.html)
TW (1) TWI893018B (cg-RX-API-DMAC7.html)
WO (1) WO2021087050A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
RU2020132460A (ru) * 2018-03-08 2022-04-08 Новартис Аг Применение антитела к p-селектину

Also Published As

Publication number Publication date
JP2023501155A (ja) 2023-01-18
TWI893018B (zh) 2025-08-11
MX2022005044A (es) 2022-05-16
CO2022005207A2 (es) 2022-05-10
MY209141A (en) 2025-06-24
CA3158921A1 (en) 2021-05-06
AU2020373017A1 (en) 2022-05-19
PE20221276A1 (es) 2022-09-05
CN114828826A (zh) 2022-07-29
US20220378912A1 (en) 2022-12-01
JOP20220097A1 (ar) 2023-01-30
KR20220092917A (ko) 2022-07-04
ECSP22033601A (es) 2022-05-31
CL2022001085A1 (es) 2023-02-03
WO2021087050A1 (en) 2021-05-06
EP4051236A1 (en) 2022-09-07
TW202128221A (zh) 2021-08-01
BR112022008097A2 (pt) 2022-08-02
PH12022551041A1 (en) 2023-04-24
AU2020373017B2 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US20190071496A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
US20210188964A1 (en) Solution Formulations of Engineered Anti-IL-23p19 Antibodies
US20090208492A1 (en) Lyophilized Immunoglobulin Formulations and Methods of Preparation
JP2022105056A (ja) 高濃度の抗vegf抗体を含有するタンパク質溶液製剤
US20170106090A1 (en) Liquid pharmaceutical composition of adalimumab
JPWO2008029908A1 (ja) 抗体を含有する安定な凍結乾燥医薬製剤
US20240424059A1 (en) Formulations for VEGF Receptor Fusion Proteins
AU2020373017B2 (en) Crizanlizumab containing antibody formulation
FI129383B (en) Stable anti-clever-1 antibody formulation
WO2022106976A1 (en) Stable pharmaceutical formulations of soluble fgfr3 decoys
EP3808777A1 (en) Stable liquid antibody formulations
CN116688115B (zh) 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
US20220193238A1 (en) Anti-il5r antibody formulations
KR20260074277A (ko) 항체 제형물
HK40103088A (en) Anti-il5r antibody formulations
HK40109650A (en) Formulations
HK40109619A (en) Formulations
US20250281403A1 (en) Formulations
CN116077650A (zh) 一种稳定的新冠中和抗体的药物组合物及其应用
CN120346170A (zh) 抗EpCAM和CD3双特异性抗体药物组合物
HK1204921B (en) Stable liquid formulation of etanercept
HK1204921A1 (en) Stable liquid formulation of etanercept
CN115297838A (zh) 抗内皮脂肪酶抗体的制剂
HK1215194B (en) Solution formulations of engineered anti-il-23p19 antibodies
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies